Making a Statement
Scroll Ahead
Driven to end cancer
22 research advances
Treatments that received FDA approval. A new blood test to predict who may benefit from lung cancer screening. A study that clarified the link between inflammation and pancreatic cancer. These are only a few of our researchers' achievements from the past year.
See our FY22 research highlightsFY22 by the numbers
175K+
patients
1,680
clinical trials
$1.1B
invested in research
Eric Singhi, M.D.
Assistant Professor
General Oncology
The subspecialized, personalized and multidisciplinary care that we can provide for patients is unparalleled.
A sustainable blood supply
Allie Moreno is among the thousands of MD Anderson patients who need blood transfusions as part of their treatment each year. While maintaining an adequate blood supply has been a challenge for hospitals across the country, MD Anderson has developed new ways to expand our donor pool.
Learn how MD Anderson has grown its blood supplySpecialized care gets teacher back to school
When Eric Roberson Jr. was diagnosed with a germ cell tumor in his brain, MD Anderson experts recommended a stem cell transplant, a treatment typically used for blood cancers. "The results speak for themselves," says the high school music teacher, who is now back in the classroom.
As a patient and an employee, I have a unique perspective on what makes MD Anderson #1. Thanks to you, MD Anderson, I'm still here!
Helping patients "weather the storm" of CAR T cell therapy
Subtle changes can signal significant side effects in patients undergoing CAR T cell therapy. That's why clinical nurse Jeremiah Bergeron monitors patients so closely and says it's all worth it when patients see their results.
What makes MD Anderson #1?
See what our employees say.
Our 23,000-person workforce is dedicated to preventing and treating cancer and offering hope through trials and discoveries.
